Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | FKBP1A | P62942 | 10/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3724641 | 0.98 | L3MBTL1 (0.68) | L3MBTL1FKBP1APOLBTSHRALOX15 | |
| SCHEMBL13039605 | 0.80 | ATM (0.50) | L3MBTL1POLBALDH1A1RAB9ALMNA | |
| SCHEMBL28685062 | 0.80 | L3MBTL1 (0.66) | L3MBTL1FKBP1APOLBTSHRALDH1A1 | |
| SCHEMBL5986412 | 0.79 | L3MBTL1 (0.70) | L3MBTL1FKBP1APOLBTSHRALOX15 | |
| SCHEMBL14538084 | 0.78 | ATM (0.48) | L3MBTL1POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4503439 | 0.78 | ATM (0.48) | L3MBTL1POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL424000 | 0.78 | L3MBTL1 (0.68) | L3MBTL1FKBP1APOLBTSHRALOX15 | |
| SCHEMBL10786869 | 0.78 | L3MBTL1 (0.68) | L3MBTL1FKBP1APOLBTSHRALDH1A1 | |
| SCHEMBL17490501 | 0.77 | L3MBTL1 (0.79) | L3MBTL1FKBP1APOLBTSHRALOX15 | |
| SCHEMBL24313327 | 0.76 | L3MBTL1 (0.78) | L3MBTL1FKBP1APOLBTSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016087603-A1 | PROCESS FOR PREPARING A MODIFIED NATURAL RUBBER BY MEANS OF A MODIFIER | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2016-06-09 | — | — | WO | claimed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9708320-B2 | β-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| WO-2016087603-A1 | PROCESS FOR PREPARING A MODIFIED NATURAL RUBBER BY MEANS OF A MODIFIER | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2016-06-09 | — | — | WO | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | L3MBTL1 1820/4885FKBP1A 2852/4885POLB 758/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | L3MBTL1 2363/4885FKBP1A 3178/4885POLB 1115/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | FN1, FNTB, CPN1 | L3MBTL1 2021/4885FKBP1A 2969/4885POLB 1918/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | FN1, FNTB, CPN1 | L3MBTL1 2021/4885FKBP1A 2969/4885POLB 1918/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | L3MBTL1 4674/4885FKBP1A 2462/4885POLB 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.